COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,822 Articles (22,968 medRxiv, 8,854 bioRxiv)

Most recent first Previous |  Page 1805: Articles 18041-18050  | Next

Age-dependent immune response to the Biontech/Pfizer BNT162b2 COVID-19 vaccination
Müller, L., Andree, M., Moskorz, W., Drexler, I., Walotka, L., Grothmann, R., Ptok, J., Hillebrandt, J., Ritchie, A., Rabl, D., Ostermann, P. N., Robitzsch, R., Hauka, S., Walker, A., Menne, C., Grutza, R., Timm, J., Adams, O., Schaal, H.
10.1101/2021.03.03.21251066 — Posted: 2021-03-05 Discussion: Onsite
SARS-CoV-2 Load does not Predict Transmissibility in College Students
Tian, D., Lin, Z., Kriner, E. M., Esneault, D. J., Tran, J., DeVoto, J. C., Okami, N., Greenberg, R., Yanofsky, S., Ratnayaka, S., Tran, N., Livaccari, M., Lampp, M., Wong, N., Tims, S., Norton, P., Scott, J., Hu, T. Y., Garry, R., Delafontaine, P., Hamm, L., Yin, X.-M.
10.1101/2021.03.02.21252105 — Posted: 2021-03-05
COVID Symptoms, Symptom Clusters, and Predictors for Becoming a Long-Hauler:Looking for Clarity in the Haze of the Pandemic
Huang, Y., Pinto, M. D., Borelli, J. L., Mehrabadi, M. A., Abrihim, H., Dutt, N., Lambert, N., Nurmi, E. L., Chakraborty, R., Rahmani, A. M., Downs, C.
10.1101/2021.03.03.21252086 — Posted: 2021-03-05 Discussion: Onsite
SARS-CoV-2 antibody magnitude and detectability are driven by disease severity, timing, and assay
Peluso, M. J., Takahashi, S., Hakim, J., Kelly, J. D., Torres, L., Iyer, N. S., Turcios, K., Janson, O., Munter, S. E., Thanh, C., Nixon, C. C., Hoh, R., Tai, V., Fehrman, E., Hernandez, Y., Spinelli, M. A., Gandhi, M., Palafox, M.-A., Vallari, A., Rodgers, M. A., Prostko, J., Hackett, J., Trinh, L., Wrin, T., Petropoulos, C. J., Chiu, C. Y., Norris, P. J., DiGermanio, C., Stone, M., Busch, M. P., Elledge, S. K., Zhou, X. X., Wells, J. A., Shu, A., Kurtz, T. W., Pak, J. E., Wu, W., Burbelo, P. D., Cohen, J. I., Rutishauser, R. L., Martin, J. N., Deeks, S. G., Henrich, T. J., Rodriguez-Barraquer, I., Greenhouse, B.
10.1101/2021.03.03.21251639 — Posted: 2021-03-05 Discussion: Onsite
A novel, anatomy-similar in vitro model of 3D airway epithelial for anti-coronavirus drug discovery
Zhang, Y., Ma, D., Zhang, J. D., Liu, X., Zhu, Q., Wang, L., Gao, L.
10.1101/2021.03.03.433824 — Posted: 2021-03-04
Multimeric nanobodies from camelid engineered mice and llamas potently neutralize SARS-CoV-2 variants
Xu, J., Xu, K., Jung, S. K., Conte, A., Lieberman, J., Muecksch, F., Lorenzi, J. C. C., Park, S., Wang, Z., Tessarollo, L., Bylund, T., Chuang, G.-Y., Olia, A., Teng, I.-T., Zhou, T., Stephens, T., Tsybovsky, Y., Bieniasz, P. D., Hatziioannou, T., Nussenzweig, M., Kwong, P., Casellas, R.
10.1101/2021.03.04.433768 — Posted: 2021-03-04 Discussion: Onsite
Published Anti-SARS-CoV-2 In Vitro Hits Share Common Mechanisms of Action that Synergize with Antivirals
Xing, J., Paithankar, S., Liu, K., Uhl, K., Li, X., Ko, M., Kim, S., Haskins, J., Chen, B.
10.1101/2021.03.04.433931 — Posted: 2021-03-04
Disinfection of SARS-CoV-2 contaminated surfaces of personal items with UVC-LED disinfection boxes
Bormann, M., Alt, M., Schipper, L., van de Sand, L., Otte, M., Meister, T. L., Dittmer, U., Witzke, O., Steinmann, E., Krawczyk, A.
10.1101/2021.03.03.433725 — Posted: 2021-03-04
T-cell Repertoire Characteristics of Asymptomatic and Re-detectable Positive COVID-19 Patients
Xu, J., Shi, Y., Wang, Y., Liu, Y., Lin, D., Zhang, J., Lin, J., Hu, W., He, H., Wang, W., Fan, W., Li, L., Lan, H., Lei, C., Wang, K., Wang, D.
10.1101/2021.03.03.433579 — Posted: 2021-03-04
UBXN3B Restricts Viral Pathogenesis by Maintaining Hematopoietic Homeostasis
WANG, P., Geng, T., Yang, D., Lin, T., Harrison, A., Haynes, L., Torrance, B., Wang, B., Vella, A. T., Cheng, G., Fikrig, E., Yang, L.
10.1101/2021.03.04.433919 — Posted: 2021-03-04

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).